NL-OMON46964已完成不适用
A prospective clinical follow up study with a New Press-fit Cup with initial RSA analysis (NPC). - ANEXYS TRIA
Stichting SCORE0 个研究点目标入组 28 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Suffer from primary or secondary coxarthrosis. * Be ready to participate in the follow-up examinations mentioned above * Be between 18 and 85 years old at the time of inclusion * Be a candidate for a primary implantation of a hip endoprosthesis * Be expected to recover completely * Have a BMI of 35 or less
排除标准
- •* Simultaneous participation in another clinical study or documentation with other orthopaedic implants of competitors. * Suffer from the exclusion criteria: sepsis or malignant tumours. * Have an ASA Classification > 3. * Have a revision surgery
研究者
相似试验
已完成
不适用
A prospective, multicenter clinical study to evaluate the safety profile of the FlexiSurge Adhesion Barrier for the prevention of intra-abdominal adhesion formation after laparotomyvorming van adhesies na buikchirurgieadhesion formationpostoperative adhesionsNL-OMON40303Medisse BV5
已完成
不适用
A randomized prospective clinical trial comparing OsteoActivator-P coated membranes vs Collagen Membrane-P uncoated for accelerated localized alveolar ridge preservation.dentaalloss of bone volumeNL-OMON51997Osteo-Pharma.B.V.16
已完成
3 期
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)1004090010035023MelanomaSkin cancerNL-OMON55317ektar Therapeutics12
已完成
3 期
A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosisprimary amyloidosisprimary systemic amyloidosis (PSA)10035227NL-OMON50586Millenium Pharmaceuticals7
已完成
2 期
A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer'pancreatic adenocarcinoma' 'pancreatic cancer'10017991NL-OMON46852Academisch Medisch Centrum15